文献速递技术与安全

FDA如何监管人工智能

How the FDA Regulates AI.
PubMed 文献 · Acad Radiol · 2020-01-01

本文综述美国食品药品监督管理局(FDA)对人工智能医疗器械的历史、现行与拟议监管路径。FDA提出的创新框架拟借助现行药品生产质量管理规范(cGMP)并采用全产品生命周期(TPLC)方法,若生效可能减轻开发者监管负担,同时维持严格质量标准与患者安全。

要点

  • 现行监管范式难以在患者安全与促进AI新领域发展之间取得平衡。
  • FDA拟议框架拟借助cGMP并采用全产品生命周期(TPLC)方法监管AI医疗器械。
  • 该框架若生效可能减轻开发者监管负担,同时维持严格质量标准。

核心结论

  • 现有监管范式不适于平衡患者安全与促进AI新领域发展,FDA提出的创新框架拟借助cGMP并采用TPLC方法解决这些问题。
  • 该框架若生效可能减轻开发者监管负担,同时使其遵守严格质量标准、最大化安全性并允许该领域成熟。

研究设计与样本

  • 综述,考察美国食品药品监督管理局(FDA)对人工智能医疗器械的历史、现行与拟议监管处理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Recent years have seen digital technologies increasingly leveraged to multiply conventional imaging modalities' diagnostic power. Artificial intelligence (AI) is most prominent among these in the radiology space, touted as the "stethoscope of the 21st century" for its potential to revolutionize diagnostic precision, provider workflow, and healthcare expenditure. Partially owing to AI's unique characteristics, and partially due to its novelty, existing regulatory paradigms are not well suited to balancing patient safety with furthering the growth of this new sector. The current review examines the historic, current, and proposed regulatory treatment of AI-empowered medical devices by the US Food and Drug Administration (FDA). An innovative framework proposed by the FDA seeks to address these issues by looking to current good manufacturing practices (cGMP) and adopting a total product lifecycle (TPLC) approach. If brought into force, this may reduce the regulatory burden incumbent on developers, while holding them to rigorous quality standards, maximizing safety, and permitting the field to mature.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Harvey HB, Gowda V. How the FDA Regulates AI. Acad Radiol. 2020. PMID: 31818387. doi:10.1016/j.acra.2019.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。